Immunocore(US:IMCR)2026-02-25 12:01Product Development and Clinical Trials - KIMMTRAK, the lead product, is approved in 39 countries and commercially launched in 30 countries, including the U.S., Germany, and France[588] - The company has treated over 2,000 cancer patients with KIMMTRAK and other ImmTAX product candidates, representing a significant clinical data set in solid tumors[589] - The company plans to complete enrollment in the registrational advanced melanoma trial, TEBE-AM, in the first half of 2026, with topline data expected in the second half of 2026[596] - The company submitted a Clinical Trial Application for its first autoimmune candidate, IMC-S118AI, for type 1 diabetes, expecting to dose the first patient in the first half of 2026[595] - The company plans to pursue further approval and commercialization of KIMMTRAK in additional indications and territories[639] - The company entered into a clinical trial collaboration with BMS to investigate a bispecific TCR candidate in combination with nivolumab, with no monetary consideration exchanged[649] Financial Performance - The company reported net losses of $55.3 million, $51.1 million, and $35.5 million for the years ended December 31, 2023, 2024, and 2025, respectively, with an accumulated deficit of $831.3 million as of December 31, 2025[591] - For the year ended December 31, 2025, total revenue increased by 29% to $400.0 million, driven primarily by net revenue from the sale of therapies, which rose to $400.0 million from $310.0 million in 2024[616] - Revenue from the sale of therapies in the United States was $257.0 million, a 13% increase from $226.7 million in 2024, while Europe saw a significant 79% increase to $131.4 million from $73.2 million[617] - Selling, general and administrative (SG&A) expenses increased to $165.4 million in 2025, up from $155.8 million in 2024, reflecting costs associated with commercial and business support functions[623] - Interest income decreased to $16.5 million in 2025 from $25.6 million in 2024, while interest expense also fell to $12.2 million from $18.8 million, primarily due to the repayment of the Pharmakon Loan[624] - The accumulated deficit stood at $831.3 million as of December 31, 2025, reflecting ongoing operating losses since inception[628] Research and Development Expenses - The company expects to continue incurring significant operating losses and increasing expenses as it advances product candidates through clinical development and seeks regulatory approvals[591] - The company anticipates an increase in R&D expenses as it advances existing and future product candidates through clinical studies[603] - Research and development (R&D) expenses for 2025 totaled $274.9 million, a 24% increase from $222.2 million in 2024, with external R&D expenses rising by 25% to $189.6 million[620][618] Financing and Liquidity - The company raised funds through various means, including an initial public offering and private placements, to support operations and R&D activities[590] - The company expects to finance operations through a combination of equity offerings, debt financings, and collaborations, amid challenging macroeconomic conditions[592] - As of December 31, 2025, cash and cash equivalents were $467.7 million, with marketable securities totaling $396.4 million, indicating a stable liquidity position[629][638] - The company completed a private offering of $402.5 million aggregate principal amount of Notes, with net proceeds of $389.1 million[648] - The company expects to incur payments of up to $66.0 million related to material contractual lease obligations extending to 2043[644] - The company has existing manufacturing obligations that could result in payments of up to $19.0 million, expected to increase as the pipeline advances[645] Tax and Regulatory Considerations - As of December 31, 2025, the company had accumulated tax losses available for carry forward in the UK of $525.5 million and in the US of $73.6 million[614] - The effective tax rate for relevant revenue streams benefiting from the U.K.'s "patent box" regime is 10%, with the company having filed for this relief for the 2023 and 2024 tax years[615] Risk Management - The company is exposed to interest rate, currency, credit, and liquidity risks, managed by a financial risk committee[659] - The company continually monitors credit quality and does not anticipate non-performance from financial institutions and corporations[667] - The maximum default risk corresponds to the carrying amount of financial assets shown in the Consolidated Balance Sheets[667] - A five percentage point increase in exchange rates would reduce the carrying value of net financial assets and liabilities held in foreign currencies by $6.5 million as of December 31, 2025[665] - Changes in exchange rates have caused material fluctuations in the Consolidated Statements of Operations and Comprehensive Loss due to foreign exchange gains and losses[664] - The company is not subject to interest rate risks related to other liabilities shown in the Consolidated Balance Sheets[662]